on VALBIOTIS (EPA:ALVAL)
Valbiotis and Nestlé Health Science terminate their licensing and supply agreement
Valbiotis announces an agreement with Nestlé Health Science to terminate their licensing and supply contract. Valbiotis thus recovers all intellectual property rights on TOTUM•63, their food supplement for prediabetes and type 2 diabetes.
The contract, signed in February 2020, granted Nestlé exclusive commercial rights. Cumulative payments of 12.75 million Swiss francs financed the clinical development of TOTUM•63.
Valbiotis plans to launch TOTUM•63 in France in the first half of 2025 and is exploring international partnerships. With a secure cash flow of 25 million euros at the end of 2023, the company intends to continue its commercial and strategic development.
R. H.Copyright © 2024 FinanzWire, all reproduction and representation rights reserved. Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all VALBIOTIS news